Menu Search
Equities

Emergent BioSolutions Inc

ER4:BER

Emergent BioSolutions Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)10.10
  • Today's Change-0.725 / -6.70%
  • Shares traded100.00
  • 1 Year change+360.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Emergent BioSolutions Inc's revenues fell -6.10% from 1.12bn to 1.05bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 211.60m to a larger loss of 760.50m.
Gross margin27.18%
Net profit margin-53.26%
Operating margin-44.48%
Return on assets-31.80%
Return on equity-87.44%
Return on investment-49.34%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Emergent BioSolutions Inc fell by 530.90m. However, Cash Flow from Investing totalled 212.30m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 206.30m for operations while cash used for financing totalled 535.70m.
Cash flow per share-9.07
Price/Cash flow per share--
Book value per share7.30
Tangible book value per share-2.79
More ▼

Balance sheet in USDView more

Emergent BioSolutions Inc has a Debt to Total Capital ratio of 69.06%, a higher figure than the previous year's 46.85%.
Current ratio1.06
Quick ratio0.5438
Total debt/total equity2.23
Total debt/total capital0.6906
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		6.17
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.